Proficio Capital Partners LLC Invests $298,000 in Moderna, Inc. $MRNA

Proficio Capital Partners LLC purchased a new stake in Moderna, Inc. (NASDAQ:MRNA) in the second quarter, according to the company in its most recent filing with the SEC. The firm purchased 4,251 shares of the company’s stock, valued at approximately $298,000.

Other institutional investors have also recently added to or reduced their stakes in the company. Vanguard Group Inc. increased its holdings in Moderna by 1.0% in the fourth quarter. Vanguard Group Inc. now owns 41,584,782 shares of the company’s stock valued at $1,226,335,000 after buying an additional 399,487 shares in the last quarter. BlackRock Inc. purchased a new stake in shares of Moderna during the 2nd quarter worth approximately $2,142,877,000. Capital World Investors purchased a new stake in shares of Moderna during the 4th quarter worth approximately $378,299,000. Invesco Ltd. grew its holdings in shares of Moderna by 15.7% in the 3rd quarter. Invesco Ltd. now owns 8,216,163 shares of the company’s stock worth $212,223,000 after acquiring an additional 1,115,131 shares during the period. Finally, Theleme Partners LLP acquired a new stake in shares of Moderna in the 2nd quarter worth approximately $564,272,000. Hedge funds and other institutional investors own 75.33% of the company’s stock.

Moderna Stock Performance

Shares of NASDAQ MRNA opened at $137.99 on Friday. The company has a 50-day simple moving average of $77.11 and a 200-day simple moving average of $59.73. The company has a debt-to-equity ratio of 0.09, a current ratio of 2.29 and a quick ratio of 2.18. The company has a market cap of $55.09 billion, a PE ratio of -17.27 and a beta of 0.91. Moderna, Inc. has a 12 month low of $22.28 and a 12 month high of $176.66.

Moderna (NASDAQ:MRNA) last announced its quarterly earnings data on Friday, July 31st. The company reported ($1.97) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.03) by $0.06. Moderna had a negative net margin of 141.43% and a negative return on equity of 28.30%. The business had revenue of $145.00 million for the quarter, compared to the consensus estimate of $102.93 million. During the same quarter in the prior year, the firm posted ($2.13) earnings per share. The company’s quarterly revenue was up 2.1% compared to the same quarter last year. On average, equities analysts anticipate that Moderna, Inc. will post -6.11 earnings per share for the current year.

Wall Street Analysts Forecast Growth

MRNA has been the subject of several research reports. Argus raised Moderna from a “hold” rating to a “buy” rating and set a $180.00 price objective for the company in a report on Friday. Piper Sandler reissued an “overweight” rating on shares of Moderna in a report on Monday, August 3rd. Loop Capital set a $135.00 price target on Moderna in a research report on Wednesday, August 19th. Royal Bank Of Canada reaffirmed a “sector perform” rating and set a $130.00 price target on shares of Moderna in a research note on Wednesday, August 19th. Finally, CLSA raised shares of Moderna to an “outperform” rating in a research note on Friday. Seven research analysts have rated the stock with a Buy rating, thirteen have given a Hold rating and three have assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $80.53.

Moderna News Roundup

Here are the key news stories impacting Moderna this week:

• Positive Sentiment: Moderna and Merck reported that their personalized mRNA melanoma vaccine, intismeran, combined with Keytruda, met the goals of a Phase 3 study involving 1,137 patients. The treatment reduced the risk of melanoma recurrence and distant spread versus Keytruda alone, strengthening the case for Moderna’s oncology pipeline and the commercial potential of the partnership. Reuters cancer vaccine breakthrough article
• Positive Sentiment: The U.S. FDA approved Moderna’s updated 2026–2027 Spikevax and mNEXSPIKE COVID-19 vaccines, targeting the XFG subvariant. The approval preserves access to the seasonal COVID-19 vaccine market, though future demand remains an important uncertainty. Reuters FDA approval article
• Positive Sentiment: Argus upgraded Moderna from “Hold” to “Buy” and assigned a $180 price target, indicating additional potential upside based on the company’s oncology opportunity and recent clinical progress. Argus upgrade article
• Neutral Sentiment: Jim Cramer advised a viewer to hold Moderna after the stock’s sharp rally, reflecting continued optimism about the Phase 3 cancer-vaccine result but also caution following the run-up. Jim Cramer Moderna commentary
• Negative Sentiment: Moderna priced an upsized $2.6 billion offering of zero-coupon convertible senior notes due 2032, increased from the initially proposed $2.0 billion. Proceeds may fund oncology investments and debt repayment, but the larger financing raised concerns about future share dilution and explains much of the selling pressure. Moderna convertible notes offering
• Negative Sentiment: BioNTech’s decision to halt a mid-stage personalized mRNA colorectal-cancer vaccine trial after a review weakened sentiment across the mRNA oncology sector, raising broader questions about the difficulty of translating promising technology into successful cancer treatments. BioNTech colorectal cancer trial article

Insider Buying and Selling at Moderna

In other news, President Stephen Hoge sold 53,336 shares of Moderna stock in a transaction on Monday, June 15th. The stock was sold at an average price of $51.37, for a total value of $2,739,870.32. Following the completion of the sale, the president owned 1,483,848 shares of the company’s stock, valued at $76,225,271.76. The trade was a 3.47% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Shannon Thyme Klinger sold 3,471 shares of Moderna stock in a transaction on Thursday, June 4th. The shares were sold at an average price of $50.00, for a total value of $173,550.00. Following the completion of the sale, the insider directly owned 67,468 shares of the company’s stock, valued at approximately $3,373,400. This represents a 4.89% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders own 10.80% of the company’s stock.

About Moderna

Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company’s platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.

Moderna’s flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.